Vasudev Bailey, PhD, is a Senior Partner @ ARTIS Ventures where he focuses on investing in novel and breakthrough health and life sciences companies. He is an investor in companies including Eko, Unnatural Products, Aether, IDbyDNA, Freenome, Climax Foods, Lemonaid Health, and board member at Association for Women in Sciences (AWIS), Johns Hopkins Biomedical Engineering, and The Trevor Project. He is the founder of the ARTIS Ventures Healthcare Pioneers, which brings together some of the world’s brightest minds to accelerate and incubate life-changing ideas in healthcare. He received his PhD at Johns Hopkins where he studied personalized chemotherapy and early cancer detection.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Seth Bannon is a Founding Partner @ Fifty Years, a seed fund that backs entrepreneurs solving the world's biggest problems with technology. Seth has seeded a range of startups shaping the world for the better — companies like  Memphis Meats (culturing meat to eat), Solugen (engineering enzymes to produce industrial chemicals sustainably), and Astranis (small satellites to cover the earth with Internet). Seth is also the co-founder of impact.tech, a community of entrepreneurs combining purpose with profit, and was previously the founder & CEO of startup Amicus. A graduate of Y Combinator, Seth was named twice to the Forbes 30 Under 30 list for Social Entrepreneurship.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Adam D’Augelli is a Partner @ True Ventures, a Silicon Valley-based venture capital firm founded in 2005 that invests in early-stage technology startups. At True, Adam has led the firm’s investments in Pendulum Therapeutics, Deep Genomics, InterVenn Biosciences, and more. Prior to True, Adam ran Perfect Wave Records, a small donation-based record label in the Southeast and taught “Digital Frontiers,” a course at the University of Florida exploring how the Internet and Technology are changing the global business landscape.In this podcast, Adam discusses his investing mentality when it comes to startups representing a range of markets from food, to cancer therapeutics, to security. Through his diverse interests and unique perspective, Adam has cultivated a tried and true model for investing which favors founders who are uniquely positioned to capture nascent markets and build consumer-facing solutions.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Nan Li is a Managing Director @ Obvious Ventures, where he invests in companies solving the world’s biggest problems in sustainable systems, healthy living, and people power. At Obvious, his investments have included LabGenius, Recursion Pharmaceuticals, Darwin AI, Octave Health, Zymergen, and Planet. Prior to joining Obvious, Nan has had a mix of technology, investing, and entrepreneurship experiences including early stage tech investments at Innovation Endeavors, Product, Operations, and Finance at Gigwalk, VC and management consulting at Bain, and PM at Microsoft. Nan is also an adjunct lecturer at Stanford where he teaches a course on symbolic systems in VC and entrepreneurship.Topics:Computational biology investmentsUnderstanding the biology of investmentsApplying digital approaches to biologyAddressing computational drug design skepticsManaging fund cycle expectations in deep tech investingEast vs west coast investment mindsetsThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Jessica Chao is the Director of the Clinical Innovation Center at UCSF, where she oversees operations and leads partnerships with industry and academia. She is an investor at Iterative VC and has over 15 years of experience as an operator in health services and med tech management. Previously, she has led product design in various San Francisco startups and co-founded Healtho, a consumer health information company. She is also the co-founder of one of the largest health meetups in Seattle, the Seattle Health Innovators. Jessica received her MBA from the Johns Hopkins Carey Business School while she concurrently completed her Residency in Health System Pharmacy Administration at Johns Hopkins Medicine. She also holds a Doctorate in Pharmacy and BS in Biochemistry from the University of Washington. Topics:The disconnect between innovation and implementation within large healthcare systemsSolutions to solve the implementation and execution issue; how startups should approach pilotsCommon mistakes made by startups while trying to understand customer needs or sell into large health systemsHow COVID-19 has accelerated both innovation and implementation, and what this means for the futurePractical advice for startups for partnering with/selling to healthcare systemsThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Tony Kulesa is a Co-founder @ Petri, an accelerator in Boston that backs companies developing new biotech applications and technologies in healthcare, food, industrial chemicals, and new materials. Co-founded and funded by Pillar, a venture firm co-founded by the CEOs of Cytyc, Ginkgo Bioworks, Iora Health, and 22 Boston companies, Petri draws on the resources of one of the strongest biotech ecosystems in the world to support founders from around the globe. Dr. Kulesa is an inventor and community builder. Previously, he was the founding Director of the MIT BioMakerspace, a community biology laboratory and incubator space, and an Instructor at the MIT Department of Biological Engineering. He holds a PhD from MIT, where his inventions of new platforms for drug discovery and microbial therapeutics were highlighted in Science Editor’s Choice and Nature Reviews Drug Discovery. While at MIT, he co-founded and directed 3 courses on biotech and entrepreneurship, including BiomedStartup, a course that coaches 10+ teams per year on research commercialization projects. He was a member of the founding officer team at MIT Biotech Group, and an ambassador for Breakout Labs, venture philanthropy from the Thiel Foundation to support companies bringing radical scientific discoveries out of the lab and into the market.Topics:The value of accelerators within the life sciencesVenture creation and innovation within biotech and pharmaEntering the life sciences industry from academia and other industriesThe intersection of technology & biology: Silicon meets Boston & the profile of new funds straddling both philosophies Types of risk within life sciences ventures: technical, biological, marketImpact of Covid-19 on the life sciences industry, both technological and financialInvesting and building in the life sciences revolutionThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Robert Pearl is the former CEO @ The Permanente Medical Group (1999-2017), the nation’s largest medical group, and former president of The Mid-Atlantic Permanente Medical Group (2009-2017). In these roles he led 10,000 physicians, 38,000 staff and was responsible for the nationally recognized medical care of 5 million Kaiser Permanente members on the west and east coasts. Dr. Pearl is nationally recognized as a physician leader on healthcare delivery. He hosts a popular podcast called Fixing Healthcare and is author of a Washington Post Bestseller: “Mistreated: why we think we’re getting good healthcare -- and why we’re usually wrong” (he has generously donated all the proceeds from his book to Doctors Without Borders). More recently, he has started a new weekly podcast - “Coronavirus: The Truth.” He writes regularly on Forbes and teaches at both the Stanford School of Medicine and Stanford Graduate School of Business. Dr. Pearl received his medical degree at Yale and completed a plastic surgery residency at Stanford. Visit his website to learn more.Technology companies have increasingly focused on the healthcare system, and many are excited by their potential to drive change, decrease costs, and improve outcomes. Dr. Robert Pearl discusses hype versus reality in healthcare delivery innovation and how tech can help - but also hurt.Topics:How Kaiser Permanente has become a leader in quality, access, and priceThe role of tech in the fee-for-service versus capitation debateDisruption of the fee-for-service system coming from HAVEN, self-insured employers, and off-shore care partnershipsHype versus reality in tech: how tech often approaches healthcare innovation wrongThe problem with wearablesMisaligned incentives within healthcare and techThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Rob Chess is a successful and esteemed serial biotech entrepreneur and executive. His resume is incredibly long and impressive. He is the Chairman of Nektar Therapeutics (NASDAQ: NKTR), a multi-billion dollar market cap company, where he was previously President and CEO. He is co-founder and Board member (until very recently the Chairman) of Biota Technologies, which uses DNA sequencing to optimize oil and gas production. He is a Lead Director at Twist Biosciences (NASDAQ: TWST), a public company that produces synthetic genes using an innovative high-throughput silicon-based manufacturing process. He was previously Chairman and CEO of OPX Biotechnologies, a renewable chemicals company that was sold to Cargill, and co-founder and President of Penederm, a dermatology company that went public and was acquired by Mylan Laboratories. He served in the White House in the first Bush administration, teaches at the Stanford business school, and is on the board of trustees at CalTech, and sits on the board of various other companies and organizations, among many other accomplishments.The biopharma industry is undergoing immense change as there are exciting advancements in technology and life sciences, amidst a constantly changing structural environment. Rob Chess discusses keys for success for founders and executives and explores some key trends involving scale, platforms, financing, discovery, and payment reform within biopharma.Topics:Keys to success as a founder or executive in biotechThe cyclical nature of platforms, products, and financing in biotech as an industryScale in biopharmaThe impact of tech-enabled services on biopharmaDirect-to-consumer biopharmaEroom’s Law and drug discoveryAcademia vs industry for life sciences innovationBusiness model problems that belie the lack of successes in diagnosticsIncentive structures in healthcare and how to align themBusiness school and management in healthcare and biopharmaPayment reform for specialty pharmaceuticalsWhy go into healthcare?Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Ian Tong is Chief Medical Officer @ Doctor On Demand. He is also currently Clinical Assistant Professor (Affiliated) at Stanford University Medical School. Ian has spent his career working to improve access to high quality care and brings this dedication to his work at Doctor On Demand.Prior to joining Doctor On Demand, Ian held several medical leadership roles. He served as Stanford Internal Medicine Chief Resident; Co-Medical Director of the Arbor Free Clinic; and Founder and Medical Director of The Health Resource Initiative for Veterans Everywhere (THRIVE) at the VA Palo Alto Health Care System, which was honored in 2008 by the U.S. Secretary of Veterans Affairs with the Award for Outstanding Achievement in Service to Homeless Veterans. Before becoming Chief Medical Officer, Ian served as Medical Director at Doctor On Demand.Ian is a National Collegiate Champion in Rugby at the University of California at Berkeley and was named to the All American Team in 1994. He graduated with a BA in English. He earned a medical degree from The University of Chicago – Pritzker and completed residency and Chief residency at Stanford Hospital and Clinics. He is board certified in Internal Medicine.Ian lives in the San Francisco Bay Area with his wife and three children. He is most proud of the relationships he has built working alongside his family, friends, teammates, students and colleagues to positively impact the lives of others.The COVID-19 pandemic is creating an inflection point in healthcare delivery and innovation. Telemedicine is playing a central role in combating the novel coronavirus outbreak, and the telehealth industry will emerge from the pandemic with new winners, losers, and structural changes.Topics:State of the pandemic and the role of telemedicine in combating itThe impact of COVID on the telehealth industryTelemedicine winners and losers in aftermath of COVID: from point solutions to integrated longitudinal careThe power of retail clinics both during the pandemic and long term in telehealth and care deliveryStructural and policy changes needed for future pandemics and for the advancement of telemedicineThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

BIOS Podcast brings together cutting-edge insights from Life Science industry leaders at the forefront innovation. Join us in hearing from Founders, Investors, Professors, & Pharma operating at the intersection of Technology & Biology. By Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health. Learn more @ BIOS.community / Alix.vc